Evidence map›Paper›PMID 37425294›Full record

ArticleFrontiers in human neuroscience2023

Executive functions and borderline personality features in adolescents with major depressive disorder.

Mona Albermann, Sophie Emery, Noemi Baumgartner, Michael Strumberger, Suzanne Erb, Lars Wöckel, Ulrich Müller-Knapp, Bruno Rhiner, Brigitte Contin-Waldvogel, Silke Bachmann and 4 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Frontiers in human neuroscience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03167307 (OMEGA-3 FATTY ACIDS AS FIRST-LINE TREATMENT IN PAEDIATRIC DEPRESSION. A Phase III, 36-week, Multi-centre, Double-blind, Placebo-controlled Randomized Superiority Study), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03167307 phase3completednot on this map

OMEGA-3 FATTY ACIDS AS FIRST-LINE TREATMENT IN PAEDIATRIC DEPRESSION. A Phase III, 36-week, Multi-centre, Double-blind, Placebo-controlled Randomized Superiority Study

TypeinterventionalSponsorGregor BergerRan2017 to 2022Enrolled257ConditionsDepressionArmsOmega 3 fatty acid, Placebo oil
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 2 countries.

Mona AlbermannDepartment of Child and Adolescent Psychiatry and Psychotherapy, University Hospital of Psychiatry Zurich, University of Zurich, Zürich, Switzerland.
Sophie EmeryDepartment of Child and Adolescent Psychiatry and Psychotherapy, University Hospital of Psychiatry Zurich, University of Zurich, Zürich, Switzerland.
Noemi BaumgartnerPsychiatric Hospital St. Gallen Nord, Wil, Switzerland.
Michael StrumbergerResearch Department of Child and Adolescent Psychiatry, Psychiatric University Hospitals Basel, University of Basel, Basel, Switzerland.
Suzanne ErbChild and Adolescent Psychiatric Services St. Gallen, St. Gallen, Switzerland.
Lars WöckelResearch Department of Child and Adolescent Psychiatry, Psychiatric University Hospitals Basel, University of Basel, Basel, Switzerland.
Ulrich Müller-KnappChild and Adolescent Psychiatry Klinik Sonnenhof, Ganterschwil, Switzerland.
Bruno RhinerChild and Adolescent Psychiatry Thurgau, Weinfelden, Switzerland.
Brigitte Contin-WaldvogelChild and Adolescent Psychiatric Services Baselland, Basel, Switzerland.
Silke BachmannUniversity Clinic of the Martin-Luther University Halle - Wittenberg's Medical Faculty, Halle, Germany.
Klaus SchmeckResearch Department of Child and Adolescent Psychiatry, Psychiatric University Hospitals Basel, University of Basel, Basel, Switzerland.
Gregor BergerDepartment of Child and Adolescent Psychiatry and Psychotherapy, University Hospital of Psychiatry Zurich, University of Zurich, Zürich, Switzerland.
Omega-3 Study Team
Isabelle HäberlingDepartment of Child and Adolescent Psychiatry and Psychotherapy, University Hospital of Psychiatry Zurich, University of Zurich, Zürich, Switzerland.
University of Zurich · CHUniversity of Basel · CHUniversity of St.Gallen · CHHôpital Beau-Séjour · CHKlinik Sonnenhof · CHPsychiatry Baselland · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Executive functions (EF) consolidate during adolescence and are impaired in various emerging psychiatric disorders, such as pediatric Major Depressive Disorder (pMDD) and Borderline Personality Disorder. Previous studies point to a marked heterogeneity of deficits in EF in pMDD. We examined the hypothesis that deficits in EF in adolescents with pMDD might be related to comorbid Borderline Personality features (BPF). Methods: We examined a sample of 144 adolescents (15.86 ± 1.32) diagnosed with pMDD. Parents rated their child's EF in everyday life with the Behavior Rating Inventory of Executive Function (BRIEF) and BPF with the Impulsivity and Emotion Dysregulation Scale (IED-27). The adolescents completed equivalent self-rating measures. Self- and parent-ratings of the BRIEF scores were compared with paired t-Tests. Correlation and parallel mediation analyses, ICC, and multiple regression analyses were used to assess symptom overlap, parent-child agreement, and the influence of depression severity. Results: Over the whole sample, none of the self- or parent-rated BRIEF scales reached a mean score above T > 65, which would indicate clinically impaired functioning. Adolescents tended to report higher impairment in EF than their parents. Depression severity was the strongest predictor for BPF scores, with Conclusion: On average, adolescents with depression show only subtle deficits in executive functioning. However, increased EF deficits are associated with the occurrence of comorbid borderline personality features, contributing to a more severe overall psychopathology. Therefore, training of executive functioning might have a positive effect on psychosocial functioning in severely depressed adolescents, as it might also improve comorbid BPF. Clinical trial registration: www.ClinicalTrials.gov, identifier NCT03167307.

Indexed as

adolescentsborderline personality disorderemotion regulationexecutive functioninhibitionmajor depressive disorder

Identifiers

PMID37425294
PMCPMC10325791
OpenAlexW4382139356

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.